Intermittent therapy for flare prevention and long-term disease control in stabilized atopic dermatitis: A randomized comparison of 3-times-weekly applications of tacrolimus ointment versus vehicle

Debra Breneman, Alan B. Fleischer, William Abramovits, Joshua Zeichner, Michael H. Gold, Robert S. Kirsner, Toni F. Shull, Andrew W. Crowe, Eileen Jaracz, Jon Hanifin

Research output: Contribution to journalArticle

77 Citations (Scopus)

Abstract

Background: Intermittent dosing of a topical calcineurin inhibitor for preventing atopic dermatitis (AD) disease relapse in patients with stabilized AD has not been evaluated. Objective: We sought to evaluate the long-term efficacy and safety of 3-times-weekly use of tacrolimus ointment in preventing AD disease relapse. Methods: Adult and pediatric patients with moderate to severe AD who were clear of disease after up to 16 weeks of treatment with tacrolimus ointment were randomized in a double-blind fashion to 3-times-weekly treatment with either tacrolimus ointment (0.03% or 0.1%) or vehicle for 40 weeks. The primary end point was the number of flare-free treatment days. Results: A total of 125 patients were randomized to tacrolimus and 72 patients to vehicle. The mean number of flare-free treatment days was 177 for tacrolimus and 134 for vehicle (P = .003). Median time to first relapse was 169 days for tacrolimus and 43 for vehicle (P = .037). Limitations: Generalizability to all patients seen in clinic may be limited because only patients who responded to tacrolimus ointment in the stabilization phase were randomized into the maintenance phase of the trial. Conclusions: Maintenance therapy with tacrolimus ointment was associated with significantly more flare-free days compared with vehicle, and a significantly longer time until first disease relapse.

Original languageEnglish (US)
Pages (from-to)990-999
Number of pages10
JournalJournal of the American Academy of Dermatology
Volume58
Issue number6
DOIs
StatePublished - Jun 2008

Fingerprint

Tacrolimus
Atopic Dermatitis
Ointments
Recurrence
Therapeutics
Maintenance
Pediatrics
Safety

ASJC Scopus subject areas

  • Dermatology

Cite this

Intermittent therapy for flare prevention and long-term disease control in stabilized atopic dermatitis : A randomized comparison of 3-times-weekly applications of tacrolimus ointment versus vehicle. / Breneman, Debra; Fleischer, Alan B.; Abramovits, William; Zeichner, Joshua; Gold, Michael H.; Kirsner, Robert S.; Shull, Toni F.; Crowe, Andrew W.; Jaracz, Eileen; Hanifin, Jon.

In: Journal of the American Academy of Dermatology, Vol. 58, No. 6, 06.2008, p. 990-999.

Research output: Contribution to journalArticle

Breneman, Debra ; Fleischer, Alan B. ; Abramovits, William ; Zeichner, Joshua ; Gold, Michael H. ; Kirsner, Robert S. ; Shull, Toni F. ; Crowe, Andrew W. ; Jaracz, Eileen ; Hanifin, Jon. / Intermittent therapy for flare prevention and long-term disease control in stabilized atopic dermatitis : A randomized comparison of 3-times-weekly applications of tacrolimus ointment versus vehicle. In: Journal of the American Academy of Dermatology. 2008 ; Vol. 58, No. 6. pp. 990-999.
@article{896bfd72d70b40ec8fdb7bd098277b2d,
title = "Intermittent therapy for flare prevention and long-term disease control in stabilized atopic dermatitis: A randomized comparison of 3-times-weekly applications of tacrolimus ointment versus vehicle",
abstract = "Background: Intermittent dosing of a topical calcineurin inhibitor for preventing atopic dermatitis (AD) disease relapse in patients with stabilized AD has not been evaluated. Objective: We sought to evaluate the long-term efficacy and safety of 3-times-weekly use of tacrolimus ointment in preventing AD disease relapse. Methods: Adult and pediatric patients with moderate to severe AD who were clear of disease after up to 16 weeks of treatment with tacrolimus ointment were randomized in a double-blind fashion to 3-times-weekly treatment with either tacrolimus ointment (0.03{\%} or 0.1{\%}) or vehicle for 40 weeks. The primary end point was the number of flare-free treatment days. Results: A total of 125 patients were randomized to tacrolimus and 72 patients to vehicle. The mean number of flare-free treatment days was 177 for tacrolimus and 134 for vehicle (P = .003). Median time to first relapse was 169 days for tacrolimus and 43 for vehicle (P = .037). Limitations: Generalizability to all patients seen in clinic may be limited because only patients who responded to tacrolimus ointment in the stabilization phase were randomized into the maintenance phase of the trial. Conclusions: Maintenance therapy with tacrolimus ointment was associated with significantly more flare-free days compared with vehicle, and a significantly longer time until first disease relapse.",
author = "Debra Breneman and Fleischer, {Alan B.} and William Abramovits and Joshua Zeichner and Gold, {Michael H.} and Kirsner, {Robert S.} and Shull, {Toni F.} and Crowe, {Andrew W.} and Eileen Jaracz and Jon Hanifin",
year = "2008",
month = "6",
doi = "10.1016/j.jaad.2008.02.008",
language = "English (US)",
volume = "58",
pages = "990--999",
journal = "Journal of the American Academy of Dermatology",
issn = "0190-9622",
publisher = "Mosby Inc.",
number = "6",

}

TY - JOUR

T1 - Intermittent therapy for flare prevention and long-term disease control in stabilized atopic dermatitis

T2 - A randomized comparison of 3-times-weekly applications of tacrolimus ointment versus vehicle

AU - Breneman, Debra

AU - Fleischer, Alan B.

AU - Abramovits, William

AU - Zeichner, Joshua

AU - Gold, Michael H.

AU - Kirsner, Robert S.

AU - Shull, Toni F.

AU - Crowe, Andrew W.

AU - Jaracz, Eileen

AU - Hanifin, Jon

PY - 2008/6

Y1 - 2008/6

N2 - Background: Intermittent dosing of a topical calcineurin inhibitor for preventing atopic dermatitis (AD) disease relapse in patients with stabilized AD has not been evaluated. Objective: We sought to evaluate the long-term efficacy and safety of 3-times-weekly use of tacrolimus ointment in preventing AD disease relapse. Methods: Adult and pediatric patients with moderate to severe AD who were clear of disease after up to 16 weeks of treatment with tacrolimus ointment were randomized in a double-blind fashion to 3-times-weekly treatment with either tacrolimus ointment (0.03% or 0.1%) or vehicle for 40 weeks. The primary end point was the number of flare-free treatment days. Results: A total of 125 patients were randomized to tacrolimus and 72 patients to vehicle. The mean number of flare-free treatment days was 177 for tacrolimus and 134 for vehicle (P = .003). Median time to first relapse was 169 days for tacrolimus and 43 for vehicle (P = .037). Limitations: Generalizability to all patients seen in clinic may be limited because only patients who responded to tacrolimus ointment in the stabilization phase were randomized into the maintenance phase of the trial. Conclusions: Maintenance therapy with tacrolimus ointment was associated with significantly more flare-free days compared with vehicle, and a significantly longer time until first disease relapse.

AB - Background: Intermittent dosing of a topical calcineurin inhibitor for preventing atopic dermatitis (AD) disease relapse in patients with stabilized AD has not been evaluated. Objective: We sought to evaluate the long-term efficacy and safety of 3-times-weekly use of tacrolimus ointment in preventing AD disease relapse. Methods: Adult and pediatric patients with moderate to severe AD who were clear of disease after up to 16 weeks of treatment with tacrolimus ointment were randomized in a double-blind fashion to 3-times-weekly treatment with either tacrolimus ointment (0.03% or 0.1%) or vehicle for 40 weeks. The primary end point was the number of flare-free treatment days. Results: A total of 125 patients were randomized to tacrolimus and 72 patients to vehicle. The mean number of flare-free treatment days was 177 for tacrolimus and 134 for vehicle (P = .003). Median time to first relapse was 169 days for tacrolimus and 43 for vehicle (P = .037). Limitations: Generalizability to all patients seen in clinic may be limited because only patients who responded to tacrolimus ointment in the stabilization phase were randomized into the maintenance phase of the trial. Conclusions: Maintenance therapy with tacrolimus ointment was associated with significantly more flare-free days compared with vehicle, and a significantly longer time until first disease relapse.

UR - http://www.scopus.com/inward/record.url?scp=43249125106&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43249125106&partnerID=8YFLogxK

U2 - 10.1016/j.jaad.2008.02.008

DO - 10.1016/j.jaad.2008.02.008

M3 - Article

C2 - 18359127

AN - SCOPUS:43249125106

VL - 58

SP - 990

EP - 999

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

SN - 0190-9622

IS - 6

ER -